# Sling Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sling-therapeutics

- Industry: Biotechnology
- Headquarters: Ann Arbor, US
- Website: www.slingtx.com
- Total disclosed funding: $158M
- Latest round: Series C (Sep 16, 2026)
- Investors on record: 3

## About

Based in Michigan, US, and founded in 2020, Sling Therapeutics, Inc. operates as a biopharmaceutical firm specializing in thyroid eye disease's later stages of development. In September 2026, Sling Therapeutics, Inc. raised USD 123 million in series C funding led by Forbion, with participation from Sectoral Asset Management and TPG. The firm offers Linsitinib, an oral small drug from Sling Therapeutics, which is in a Phase 2b study for thyroid eye disease (TED) and acts by blocking the confirmed IGF-1R target. Linsitinib has a proven safety profile after treating over 800 individuals and is being studied for the treatment of other autoimmune and uncommon disorders. The firm intends to use the funds raised in September 2026 to support late-stage clinical development and advance an oral treatment for thyroid eye disease through a pivotal trial.

## Funding rounds

- Series C, Sep 16, 2026, $123M — TPG, Forbion, Sectoral Asset Management
- Series A, Jun 13, 2022, $35M — TPG

## Investors

- TPG (https://capitalatlas.ai/funds/tpg) — Series A, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series C